<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:463354422;
mso-list-template-ids:-800044520;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1192692243;
mso-list-template-ids:1456615142;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1304000892;
mso-list-template-ids:-1038183336;}
@list l3
{mso-list-id:1353917975;
mso-list-template-ids:77337550;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4
{mso-list-id:1719433619;
mso-list-type:hybrid;
mso-list-template-ids:-1537719244 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5
{mso-list-id:2018195676;
mso-list-type:hybrid;
mso-list-template-ids:877054350 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l5:level1
{mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level2
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level3
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
@list l5:level4
{mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level5
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level6
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
@list l5:level7
{mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level8
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l5:level9
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://forefdn.org/wp-content/uploads/2021/05/Innovation_RFP_FINAL.pdf">Foundation for Opioid Response Efforts: Opioid Crisis Innovation Challenge 2021</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Foundation for Opioid Response Efforts (FORE) will provide grant support for specific projects that bring an innovative approach to long-standing and complex issues related to all
aspects of stemming the tide of the nation’s opioid crisis. This RFP targets projects which can explore and/or evaluate new “outside-the-box” ideas, bring together approaches from several diverse fields, and engage multi-disciplinary, cross-sector teams to
solve some of the crisis’ most intractable problems. Currently, this opportunity will focus on projects in the following three areas which, based on discussions with experts in the field, are widely recognized challenges to adequately address the opioid crisis
with few examples of how to approach differently to accelerate improvements in reducing overdoses, increasing access to treatment, and supporting long-term recovery:
<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo3"><b><span style="font-size:12.0pt;font-family:Palatino">Professional Education and Training</span></b><span style="font-size:12.0pt;font-family:Palatino">. Stigma towards those with
addiction continues to be a barrier to evidence-based treatment, as well as to the resources and capital a person needs to sustain long-term recovery, such as employment. While there is an increase in available professional education on addiction and recovery
among healthcare, education, legal, criminal justice, and other professionals, these are still not routinely taught. Projects in this focus area may include innovative new approaches to educating professionals and addressing stigma within these and other settings.
<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo3"><b><span style="font-size:12.0pt;font-family:Palatino">Timely and Actionable Data.</span></b><span style="font-size:12.0pt;font-family:Palatino"> Real-time and actionable data is still
severely lacking for all levels of government to appropriately respond to the crisis. The COVID-19 pandemic shined a light on how to utilize new emerging technologies to create new data systems for tracking public health crises in real-time. Projects in this
focus area may include integrating new and untapped data sources across different sectors to generate a more in-depth understanding of the crisis, as well as applying new emerging technologies (such as machine learning and artificial intelligence) to aid in
national, state, and local government responses. <o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo3"><b><span style="font-size:12.0pt;font-family:Palatino">Supporting the Transition from Treatment to Recovery.</span></b><span style="font-size:12.0pt;font-family:Palatino"> While much
focus has been put on access to treatment, there is a great need to aid those transitioning from treatment to recovery. As individuals facing transitions or life course changes are often at increased vulnerability, it is important that we “meet patients where
they are.” Projects in this focus area may include novel uses of technology, such as digital and mobile apps, as well as other innovative ways to support those transitioning to long-term recovery.<o:p></o:p></span></li></ol>
<p class="MsoNormal" style="margin-left:.25in"><span style="font-size:12.0pt;font-family:Palatino">$300,000 / year for 2-year projects.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Concept note due July 19, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: July 6.</span></span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.25in"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.cureswithinreach.org/wp-content/uploads/2021/06/CWR-Repurposing-Research-Led-by-a-US-Based-Racial-Minority-PI-2021-1.pdf">Cures Within Reach: Repurposing Research
Led by a US-Based Racial/Ethnic Minority Principal Investigator</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Cures Within Reach (CWR) works to improve patient quality and lifespan by leveraging the speed, safety, and cost-effectiveness of medical repurposing research, driving more treatments
to more patients more quickly. To that end, CWR has issued a Request for Proposals seeking clinical repurposing trials in any disease led by a racial/ethnic minority that is underrepresented in biomedical research (as defined by the NIH): Blacks or African
Americans, Hispanics or Latinx, American Indians or Alaska Natives, and Native Hawaiians and other Pacific Islanders. CWR is interested in approved generic or proprietary drugs, devices, nutraceuticals, or diagnostics that could be repurposed to create “new”
treatments to reduce the symptoms, progression, or incidence of; restore function lost to; reduce or eliminate severe side effects of currently used therapies for any unmet medical need. Repurposed therapies can be used alone or in combination with other therapies
or repurposed from an approved adult indication into a pediatric indication. Therapies must already be approved by the FDA, EMA, or any other regulatory agency or otherwise readily available for human use. At least three grants of up to $70,000 each will be
funded through this RFP.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 30 (extended from July 9), 2021.
<span style="color:red">Med-RA deadline to receive draft documents: July 19.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-012.html" target="_blank">Assessing the Effects of Cannabinoids on HIV-Induced Inflammation (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic science and preclinical research to determine the biological mechanisms underlying 1) the effects of cannabinoids
and the endocannabinoid system on HIV-associated persistent inflammation, and 2) its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 5, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: July 26.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="http://www.krhofmann.org/about-us" target="_blank">Kent Richard Hofmann Foundation HIV/AIDS Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The foundation is accepting Letters of Intent from community-based organizations working in the areas of HIV/AIDS care and direct services, education, and research. Grants
will be awarded in support of developing or established programs, with emphasis on the direct benefit to clients or the target audience. Requests from anywhere in the U.S. will be considered, with a focus on smaller communities and rural areas.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Priority will be given to requests from communities with limited access to funding; requests for seed money for new projects, programs, or structures; and/or innovative ideas
for meeting basic needs. Grant amounts will be determined on a project-by-project basis.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Letter of inquiry due August 6, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: July 26.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/cpmrp" target="_blank">Chronic Pain Management Research Program</a><br>
<b>Clinical Exploration Award</b><br>
Pre-application (preproposal): July 30. Invited full application: November 12.<br>
<b>Investigator Initiated Research Award</b><br>
Pre-application (preproposal): July 30. Invited full application: November 12.<br>
<b>Translational Research Award</b><br>
Pre-application (preproposal): July 30. Invited full application: November 12.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for preproposal: July 19.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/kcrp" target="_blank">Kidney Cancer Research Program</a><br>
<b>Academy of Kidney Cancer Investigators – Early-Career Investigator Award</b><br>
Pre-application (required letter of intent): September 14, 2021. Full application: October 5, 2021.<br>
<b>Clinical Research Nurse Development Award</b><br>
Pre-application (required letter of intent): September 14, 2021. Full application: October 5, 2021.<br>
<b>Clinical Trial Award</b><br>
Pre-application (required letter of intent): September 14, 2021. Full application: October 5, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: September 22.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/lrp" target="_blank">N</a><a href="https://cdmrp.army.mil/funding/netp" target="_blank">eurotoxin Exposure Treatment Parkinson’s</a><br>
<b>Early Investigator Research Award</b><br>
Pre-application (required letter of intent): September 8. Full application: September 29.<br>
<b>Investigator Initiated Research Award</b><br>
Pre-application (required letter of intent): September 8. Full application: September 29.<br>
<b>Synergistic Idea Award</b><br>
Pre-application (required letter of intent): September 8. Full application: September 29.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: September 16.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/srp" target="_blank">Scleroderma Research Program</a><br>
<b>Idea Development Award</b><br>
Pre-application (required letter of intent): August 11. Full application: August 25.<br>
<b>Translational Research Partnership Award</b><br>
Pre-application (required letter of intent): August 11. Full application: August 25.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: August 12.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Exploratory/Developmental Research Projects (UH2 / U01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-014.html" target="_blank">UH2</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-010.html">U01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded “Collaborative Initiative on Fetal Alcohol Spectrum Disorders” (CIFASD).
Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and
accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD.<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects of the CIFASD
consortium.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l4 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Cooperative Agreement (U01) applications in response to this FOA should propose individual clinical or basic research projects.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 16, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: August 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-016.html" target="_blank">NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The <a href="https://commonfund.nih.gov/newinnovator/index">
NIH Director’s New Innovator Award Program</a> supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH.
For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full
spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to,
topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director’s New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and
Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the
<a href="https://commonfund.nih.gov/highrisk/">High-Risk, High-Reward Research (HRHR) Program</a> of the
<a href="https://commonfund.nih.gov/">NIH Common Fund</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 20, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: August 9.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-226.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-225.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements invite research grant applications that propose studies for adapting immunotherapy and gene therapy-based strategies to target viral reservoirs
in the central nervous system and examine the potential risks of applying such technologies to the brain. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged
but not required.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 27, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: August 16.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-013.html" target="_blank">NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The <a href="https://commonfund.nih.gov/TRA">
NIH Director’s Transformative Research Award Program</a> supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms,
establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce.
Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications
are welcome in all topics relevant to the broad mission of NIH, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary
data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Director’s Transformative Research Award is a component of the
<a href="http://commonfund.nih.gov/highrisk/">High-Risk, High-Reward Research (HRHR) Program</a> of the
<a href="http://commonfund.nih.gov/">NIH Common Fund</a><b>. </b><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: August 19.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://leo-foundation.org/en/grants-and-awards/research-grants/" target="_blank">Leo Foundation: Dermatology Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">LEO Foundation Open Competition grants are given to support the best dermatology research projects worldwide. Thus, we welcome applications from research projects that:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Improve the understanding of the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life and
the societal costs involved.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 7, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: August 24 (due to Labor Day holiday).<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-232.html">Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical
Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement
comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-275.html">The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through
which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21s / R01s)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-030.html">R21 – Basic Experimental Studies with Humans Required</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-005.html">R21 – Clinical Trial Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-024.html">R01 Basic Experimental Studies with Humans Required</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-007.html">R01 Clinical Trial Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These funding opportunity announcements invite mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant
mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 4.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-011.html" target="_blank">Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid
action in the rodent brain (R01 – Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce
and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on single-cell resolution approaches that enable multimodal high-throughput functional mapping, anatomical characterization
and molecular profiling of cell assemblies identified as targets of, or as primary sources of opioids in the brain.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 15, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-250.html" target="_blank">Mechanisms of Alcohol Tolerance</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop
hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be
accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the
R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-025.html">Data Enhancements and Analyses to Clarify the Relationship between Education and Cognitive Function (including
AD/ADRD) (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications that propose to add enhanced measures of educational experiences, cognitive function, or both to existing studies and/or
to conduct analyses that incorporate these measures to clarify the relationship between education, cognition, and risk of Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD), including the role of education in social disparities in AD/ADRD
outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">October 20, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 7.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>